Clinical trials
Hematology clinical trials
Below are recruiting hematology clinical trials, each written for real people, not researchers. We’re tracking 602 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06904066RecruitingPhase 1
Custom T cells for blood cancers with specific mutations
This trial tests a personalized treatment where your immune cells are collected, modified to recognize unique cancer markers (neoantigens) from TP53 or RAS mutations, and returned to fight blood cancers like AML, MDS, or multiple myeloma.
Bethesda, MarylandAges 18–120 - NCT05388695RecruitingPhase 1
Testing dual-target CAR T cells for B-cell blood cancers
This Phase 1 study tests CAR T cells designed to attack B-cell blood cancers using two targets (CD19 and CD20/CD22). It may help people whose cancer has come back or not responded to standard treatments, but it is mainly to check safety and early effectiveness.
Wuhan, HubeiAges 18–70 - NCT07234110Recruiting
CD5 CAR-T therapy for returning blood cancers
This trial tests a new treatment using your own immune cells, modified to find and attack cancer cells that have a CD5 marker. It may be an option for people with certain lymphomas or leukemia that have not responded to standard treatments or have come back.
Tianjin, Tianjin MunicipalityAges 1–70 - NCT06607289Recruiting
Blood cancer patients on CAR-T therapy long-term study
This study is for people with blood cancers who are treated with CAR-T cell therapy. Researchers will follow participants over time to learn more about how this therapy works in the real world.
Tianjin, Tianjin MunicipalityAges Any age - NCT07185503Recruiting
Testing two antifungal drugs for mucormycosis with blood cancer
This trial tests a combination of two antifungal medications (liposomal amphotericin B and posaconazole or isavuconazole) to treat a serious fungal infection called mucormycosis in people with blood cancers like leukemia or lymphoma. The goal is to see if this combination is safe and works well.
DalianAges 18–65 - NCT07172191Enrolling by invitation
Fecal transplant for adults with blood cancer and infections
This trial tests whether transplanting healthy donor bacteria (fecal microbiota) into the gut can help adults with blood cancers who have stubborn infections, C. diff, or complications after stem cell transplant. It may reduce dangerous germs and improve gut health.
Budapest, BudapestAges Any age - NCT04707300RecruitingPhase 1/Phase 2
HTLP injection to speed immune recovery after cord blood transplant
This Phase 1/2 study tests whether a specific immune-cell “starter” injection (HTLP) can help adults rebuild their immune system faster after an umbilical cord blood transplant for blood cancers. It mainly focuses on safety and whether immune recovery improves.
ParisAges 18–66 - NCT05470491RecruitingPhase 1/Phase 2
Haploidentical bone marrow transplant with GVHD prevention drugs
This trial tests a reduced-intensity bone marrow transplant from a related donor (haploidentical), using medicines to help prevent a serious complication called GVHD. It is for people with certain blood cancers and aims to improve outcomes by balancing transplant benefit with lower treatment intensity.
Bethesda, MarylandAges 12–120 - NCT07629726RecruitingPhase 1/Phase 2
Study of KK2430 for Blood Cell Cancers
This is an early-stage study testing a new drug called KK2430 in people with blood cancers (like leukemia or lymphoma). The goal is to find the right dose and see if it helps shrink tumors.
Greenville, South CarolinaAges 18 years+ - NCT05011422RecruitingPhase 1
Haploidentical stem cell transplant for high-risk leukemia in children
This early-phase study tests a transplant using a “partially matched” (haploidentical) donor’s stem cells, with extra lab steps to reduce certain immune cells. It is designed for children with high-risk blood cancers to lower relapse risk and improve outcomes.
St Louis, MissouriAges Up to 30 years - NCT04733729Recruiting
COVID-19 in blood cancer patients
This study looks at COVID-19 in people who have (or have had) blood cancers and are positive for SARS‑CoV‑2. It may help doctors understand how COVID-19 affects people with blood cancers and guide care.
BresciaAges 18–99 - NCT02586389Recruiting
Blood and tumor samples for a liquid biopsy test
This study collects blood and may also use existing tumor tissue to help develop a liquid biopsy blood test for people with solid (non-blood) cancers. You may qualify if you have a current cancer with tumor in the body and can provide blood samples at set visits.
Boise, IdahoAges 18 years+ - NCT05009537Recruiting
Optical genome testing for blood cancer diagnosis
This study tests a special way of looking at chromosomes to help diagnose blood-related cancers or blood disorders. If you’re having samples taken for chromosome testing, this trial may use your sample to see if the method helps with diagnosis.
BrestAges Any age - NCT06548958Recruiting
TBI and chemotherapy before a second stem cell transplant
This trial tests a combination of total body irradiation and two chemotherapy drugs as preparation for a second stem cell transplant in people with blood cancers that relapsed or didn't respond to the first transplant.
Suzhou, JiangsuAges 14–70 - NCT07670949Recruiting
68Ga-EV203 imaging for blood cancers
This trial uses a special imaging agent called 68Ga-EV203 to see where certain blood cancers (multiple myeloma, non-Hodgkin lymphoma, or acute myeloid leukemia) are located in the body. It helps doctors understand how the agent spreads and how safe it is.
Hangzhou, ZhejiangAges 18–75 - NCT07113925RecruitingPhase 1
Testing TQB2101 for advanced blood cancers
This trial tests a new drug called TQB2101 for people with advanced blood cancers that haven't improved with standard treatments. The goal is to see if the drug is safe and effective.
Zhengzhou, HenanAges 18–75 - NCT04728893RecruitingPhase 2
Nemtabrutinib for blood cancers after prior treatment
This Phase 2 trial tests nemtabrutinib (MK-1026), an oral medicine, in people with certain blood cancers that have come back or didn’t respond to earlier treatments. It aims to see how well the drug works and whether it is safe.
Springdale, ArkansasAges 18 years+ - NCT05110742RecruitingPhase 1/Phase 2
CD5-targeting NK cell therapy for blood cancers
This trial tests a new kind of immune cell therapy (NK cells) that are made to attack cancer cells carrying the CD5 marker. You will have a short course of chemotherapy before the infusion to help the cells work. It is for people with certain blood cancers that have not responded to standard treatments.
Houston, TexasAges 18 years+ - NCT07285668Recruiting
Special donor immune cells after stem cell transplant for high-risk blood cancers
This study tests whether giving specially treated donor immune cells after a stem cell transplant can help prevent relapse in patients with high-risk blood cancers. You would get a stem cell transplant from a relative, followed by an infusion of donor cells that have been processed to reduce the risk of graft-versus-host disease.
Madison, WisconsinAges 18–80 - NCT07579065Recruiting
Care Plan Support After Blood Cancer Stem Cell Transplant
This study tests whether a personalized care plan helps blood cancer patients and their caregivers manage life after stem cell transplant. Researchers want to see if this plan makes recovery smoother and improves quality of life.
Reggio EmiliaAges 18 years+ - NCT07572006RecruitingPhase 1
Study of JNJ-95804306 for blood cancers that returned or didn't respond
This trial tests a new drug called JNJ-95804306 for people with certain blood cancers (like acute myeloid leukemia, myelodysplastic syndromes, or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. The goal is to see if the drug is safe and if it can help.
Indianapolis, IndianaAges 18 years+ - NCT03328078RecruitingPhase 1/Phase 2
Emavusertib for recurrent brain lymphoma after prior treatment
This Phase 1/2 trial tests emavusertib (a targeted medicine) in adults with primary central nervous system lymphoma that has come back or not responded to treatment. It’s designed to find safe dosing and see how well the treatment can control the lymphoma in the brain/spinal fluid.
Phoenix, ArizonaAges 18 years+ - NCT03537482RecruitingEarly Phase 1
Testing a new drug for blood cancers in adults
This early trial studies how safe and tolerable APG-2575 is, and how the drug moves through the body, in adults with certain relapsed or hard-to-treat blood cancers. It may help researchers learn whether the treatment could work better for people who have limited options.
Jacksonville, FloridaAges 18 years+ - NCT03557619RecruitingPhase 1
Venetoclax test in women with specific non-Hodgkin lymphomas
This Phase 1 study tests how venetoclax affects certain hormone pills (ethinyl estradiol and levonorgestrel) in women with different non-Hodgkin lymphomas. It’s mainly looking at safety and drug interactions, which could help guide treatment for people who need hormone-based contraception.
Detroit, MichiganAges 18 years+
Hear when a new Hematology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematology?
- Yes. Clin2 currently lists 602 recruiting hematology studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematology trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematology trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.